# Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study

> **NCT06990061** · NA · NOT_YET_RECRUITING · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 50 (estimated)

## Conditions studied

- Non-Muscle Invasive Bladder Cancer

## Interventions

- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT06990061
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2031-09-18
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06990061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06990061, "Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06990061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*